User's guide for THERMIT-2 : a version of THERMIT for both core-wide and subchannel analysis of light water reactors

This report provides the THERMIT-2 user with programming and input information. THERMIT-2 is the most recent version of THERMIT. This new version contains all of the features and options of the original version of THERMIT documented in References 1 and 2. Additionally, the ability to analyze subchannels as well as improved modeling have been added to the code. These new additions are described in detail in Reference 3. The interested reader is referred to these references for further information about the physical modeling.In this report, the programming information is given first. This information includes details concerning the code and data structure. The description of the required input variables is presented next. After the meanings of these variables are given, the sample problems are described and the THERMIT-2 results are presented.THERMIT-2 contains subroutines from the IMSL Library, a proprietary package from International Mathematical and Statistical Libraries, Inc., Houston, Texas. These routines may not be redistributed or removed from this software for use in other software development, IMSL routines included are: LEQTIB, UERTST and UGETIO

Bezlotoxumab for prevention of recurrent Clostridium difficile infection in patients at increased risk for recurrence

Background: Bezlotoxumab is a human monoclonal antibody against Clostridium difficile toxin B indicated to prevent C. difficile infection (CDI) recurrence (rCDI) in adults at high risk for rCDI. This post hoc analysis of pooled monocolonal antibodies for C.difficile therapy (MODIFY) I/II data assessed bezlotoxumab efficacy in participants with characteristics associated with increased risk for rCDI. Methods: The analysis population was the modified intent-to-treat population who received bezlotoxumab or placebo (n = 1554) by risk factors for rCDI that were prespecified in the statistical analysis plan: age ≥65 years, history of CDI, compromised immunity, severe CDI, and ribotype 027/078/244. The proportion of participants with rCDI in 12 weeks, fecal microbiota transplant procedures, 30-day all cause and CDI-associated hospital readmissions, and mortality at 30 and 90 days after randomization were presented. Results: The majority of enrolled participants (75.6%) had ≥1 risk factor; these participants were older and a higher proportion had comorbidities compared with participants with no risk factors. The proportion of placebo participants who experienced rCDI exceeded 30% for each risk factor compared with 20.9% among those without a risk factor, and the rCDI rate increased with the number of risk factors (1 risk factor: 31.3%; ≥3 risk factors: 46.1%). Bezlotoxumab reduced rCDI, fecal microbiota transplants, and CDI-associated 30-day readmissions in participants with risk factors for rCDI. Conclusions: The risk factors prespecified in the MODIFY statistical analysis plan are appropriate to identify patients at high risk for rCDI. While participants with ≥3 risk factors had the greatest reduction of rCDI with bezlotoxumab, those with 1 or 2 risk factors may also benefit. Clinical Trials Registration: NCT01241552 (MODIFY I) and NCT01513239 (MODIFY II)

Proteomic analyses of Urine Exosomes reveal New Biomarkers of Diabetes in Pregnancy.

ObjectiveTo evaluate 24 hour urine exosome protein content changes among pregnant US subjects with diabetes and obesity during early pregnancy.MethodsThe exosome proteome content from 24 hour urine samples of pregnant subjects with gestational diabetes mellitus (GDM, N=8) and pre-gestational Type 2 diabetes (PGD, N = 10) were compared with control samples (CTRL, N = 10) obtained at week 20 of pregnancy. Differences in exosome protein load between groups was identified by liquid chromatography/mass spectrometry, analyzed by linear regression in negative binomial distribution, visualized in MetaboAnalyst (version 3.0), and validated by western immunoblotting.ResultsAt the 20th week of pregnancy, we identified 646, 734 and 856 proteins in exosomes from 24 hour urine samples of patients from the CTRL, GDM and PGD groups, respectively. S100 calcium binding protein A9, damage associated molecular pattern (DAMP) signal, was found to be significantly increased in both GDM and PGD subjects. In GDM subjects the peptide counts for S100A9 protein independently correlated with maternal obesity and macrosomia of the newborn infants. Early to late pregnancy developmental changes in the GDM group were shown to utilize pathways and protein expression levels differently from those in PGD or CTRL groups.ConclusionsUrinary exosome proteomic analysis non-invasively provides insights into maternal changes during diabetic pregnancy. Exosome biomarkers early in pregnancy can be potentially used to better understand pathophysiologic mechanisms of diabetes at a cellular level, and to distinguish between gestational and pre-gestational diabetes at the pathway level. This information can aid intervention efforts to improve pregnancy outcomes in women with diabetes

Correlates of Continued Alcohol Consumption During Pregnancy: Implications for Health Promotion

Purpose: Too many women continue to drink alcohol during recognized pregnancy. This purpose of this study was to explore factors related to alcohol use during pregnancy. Design: Data came from reviews of charts from women that called the California Teratogen Information Service (CTIS) at some point during the time period from 1981 and 2006 and enrolled in a pregnancy outcome study. Subjects: Approximately 40% of the 181 women in the study sample were 25 years of age and younger, and most women had not previously given birth (61.3%). Measures: Chart extraction data included whether or not women discontinued alcohol consumption at anytime during pregnancy, at what point in their pregnancy they first contacted CTIS, and other demographic information. Results: Approximately 20% of women continued to drink alcohol throughout pregnancy and 37.6% contacted CTIS after the first trimester. Initiating contact with CTIS after the first trimester (p < .01) and being older than 25 years of age (p < .05) were both associated with continued drinking throughout pregnancy. Conclusion: Older women, still of reproductive age, may benefit most from health promotion interventions that focus on alcohol consumption during pregnancy

Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies Are Clinicians Responding Optimally?

ObjectivesThe purpose of this study was to examine treatment practices for cancer therapy-associated decreased left ventricular ejection fraction (LVEF) detected on echocardiography and whether management was consistent with American College of Cardiology/American Heart Association guidelines.BackgroundPatients treated with anthracyclines or trastuzumab are at risk of cardiotoxicity. Decreased LVEF represents a Class I indication for drug intervention according to American College of Cardiology/American Heart Association guidelines.MethodsPatients receiving anthracycline or trastuzumab at Stanford University from October 2005 to October 2007 and who had undergone echocardiography before and after receiving an anthracycline or trastuzumab were identified. Chart review examined chemotherapy regimens, cardiac risk factors, imaging results, concomitant medications, and cardiology consultations.ResultsEighty-eight patients received therapy with an anthracycline or trastuzumab and had a pre-treatment and follow-up echocardiogram. Ninety-two percent were treated with anthracyclines, 17% with trastuzumab after an anthracycline, and 8% with trastuzumab without previous treatment with anthracycline. Mean baseline LVEF was 60%, with 14% having a baseline <55%. Forty percent had decreased LVEF (<55%) after anthracycline and/or trastuzumab treatment. Of these patients, 40% received angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy, 51% beta-blocker therapy, and 54% cardiology consultation. Of patients with asymptomatic decreased LVEF, 31% received angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy, 35% beta-blocker therapy, and 42% cardiology consultation. Of those with symptomatic decreased LVEF, 67% received angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy, 100% beta-blocker therapy, and 89% cardiology consultation.ConclusionsMany cancer survivors are not receiving treatment consistent with heart failure guidelines. There is substantial opportunity for collaboration between oncologists and cardiologists to improve the care of oncology patients receiving cardiotoxic therapy

Non-Equilibrium Statistical Physics of Currents in Queuing Networks

We consider a stable open queuing network as a steady non-equilibrium system of interacting particles. The network is completely specified by its underlying graphical structure, type of interaction at each node, and the Markovian transition rates between nodes. For such systems, we ask the question ``What is the most likely way for large currents to accumulate over time in a network ?'', where time is large compared to the system correlation time scale. We identify two interesting regimes. In the first regime, in which the accumulation of currents over time exceeds the expected value by a small to moderate amount (moderate large deviation), we find that the large-deviation distribution of currents is universal (independent of the interaction details), and there is no long-time and averaged over time accumulation of particles (condensation) at any nodes. In the second regime, in which the accumulation of currents over time exceeds the expected value by a large amount (severe large deviation), we find that the large-deviation current distribution is sensitive to interaction details, and there is a long-time accumulation of particles (condensation) at some nodes. The transition between the two regimes can be described as a dynamical second order phase transition. We illustrate these ideas using the simple, yet non-trivial, example of a single node with feedback.Comment: 26 pages, 5 figure

A new measurement of the structure functions PLL−PTT/epsilonP_{LL}-P_{TT}/epsilon and PLTP_{LT} in virtual Compton scattering at Q2=Q^2= 0.33 (GeV/c)2^2

The cross section of the $ep \to e' p' \gamma$ reaction has been measured at $Q^2 = 0.33$ (GeV/c)$^2$. The experiment was performed using the electron beam of the MAMI accelerator and the standard detector setup of the A1 Collaboration. The cross section is analyzed using the low-energy theorem for virtual Compton scattering, yielding a new determination of the two structure functions P_LL}-P_{TT}/epsilon and $P_{LT}$ which are linear combinations of the generalized polarizabilities of the proton. We find somewhat larger values than in the previous investigation at the same $Q^2$. This difference, however, is purely due to our more refined analysis of the data. The results tend to confirm the non-trivial $Q^2$-evolution of the generalized polarizabilities and call for more measurements in the low-$Q^2$ region ($\le$ 1 (GeV/c)$^2$).Comment: 9 pages, 10 figures. EPJA version. slight revisions in the text and figure

Detecting Higgs Boson Decay to Neutralinos at Hadron Supercolliders

We examine prospects for detecting the neutral Higgs bosons of minimal supersymmetric models (MSSM) when their decays into neutralino pairs are kinematically allowed. The best signature appears to be H_h,H_p\to\tz_2\tz_2\to 4\ell +\eslt. We argue that Standard Model contributions to this signature are negligible, and examine regions of MSSM parameter space where the four lepton mode should be observable at the Large Hadron Collider. The same signal can also come from continuum neutralino pair production. We propose a set of cuts to illustrate that the neutralino decay mode of the Higgs bosons provides a viable signal over a substantial range of model parameters, and show that it may be separable from continuum neutralino production if sufficient integrated luminosity can be accumulated.Comment: 15 pages (REVTEX), 7 figures available by regular mail, FSU-HEP-940204, UH-511-781-9